首页|Antibiotics: the economics must support the science
Antibiotics: the economics must support the science
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
The bacterium Acinetobacter baumannii is a portrait of resilience. The microorganism causes a range of infections, and its ability to survive desiccation means it can persist for weeks on hospital air vents, computer keyboards and human skin. Its metabolic and genetic flexibility have allowed it to become resistant to the few antibiotics that can make it through its two protective cell membranes. Antibiotic-resistant microbes kill more than one million people each year. Theglobal threat posed by A. baumannii has put the microbe high on the list of priority pathogens drawn up by the World Health Organization (WHO). Two studies published on 3January in Nature report a new class of drug candidates for tackling/1, baumannii infections.One of these compounds has already made it into clinical trials, but it is still a long way from being approved for clinical use. The obstacles for developing such compounds are not just scientific: the economic incentives are insufficient for many companies to take the risk. As the threat of resistance grows, the international community must do more to shepherd promising drugs from bench to bedside.
NETL
NSTL
